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Abstract 
Objective: The aim of this study was to clone PPARγ1 cDNA in an appropriate mammalian 
expression vector, with a chimeric cDNA form, encompassing PPARγ with enhanced green 
fluorescent protein (EGFP) cDNA. This recombinant plasmid will be used for further analy-
ses to investigate the molecular mechanism of PPARγ1 for neural differentiation process. 
Moreover, the nuclear localization of the PPARγ1 protein linked to EGFP marker was chased 
by using transient transfection of a constructed plasmid into bovine fibroblast cells.
Materials and Methods: Total RNA was extracted from the fatty tissue of an adult mouse. 
Using specific pair primers, PPARγ1 cDNA was synthesized and amplified to produce 
the entire length of ORF. RT-PCR products containing PPARγ1 cDNA were treated by 
enzymatic digestion and inserted into the pEGFP-C1 downstream from EGFP cDNA. The 
constructed vector was used for transformation into bacterial competent cells. Positive 
colonies which showed inserted PPARγ1 cDNA were selected for plasmid preparations 
and additional analysis was performed to ensure that PPARγ1 cDNA was inserted prop-
erly. Finally, to confirm the intracellular localization of EGFP-PPARγ1, bovine fibroblast 
cells were transfected with the recombinant plasmid.
Results: Our results from enzymatic digestion and sequencing confirmed, as expected, that 
PPARγ1 cDNA was amplified and cloned correctly. This cDNA gene encompassed 1428 bp. 
The related product was entered into the nucleus of bovine fibroblasts after transfection of 
its cDNA.
Conclusion: PPARγ1 cDNA was cloned and sorted into nuclear compartments of bovine 
fibroblast cells upon transfection.
Keywords: PPARγ, Nuclear Targeting, Enhanced Green Fluorescent protein, Cloning, 
Transfection
Introduction
Peroxisome proliferator-activated receptors (PPARs) 
are a family of nuclear receptors that mainly act as 
transcription factors which control regulation of the 
expression of specific genes (1). Thus PPARs ex-
ert their regulations on various cellular functions 
including cellular differentiation, development, 
and metabolism in mammals (2, 3). Three types of 
PPARs have been identified so far: alpha, beta/delta 
and gamma. PPARα (alpha) is expressed mainly in 
liver, kidney, heart, muscle, and adipose tissue; while 
β/δ (beta/delta) show expression in a broad range 
of tissues, markedly in the brain. In adipose tissue, 
PPARγ (gamma) expression is high. PPARs have 
been originally identified in Xenopus as a type of 
receptor which induces the proliferation of peroxi-
somes in cells (4). The best-known PPAR ligands 
are thiazolidinediones (5). All PPARs heterodimer-
ize with the retinoid X receptor (RXR) and bind to 
specific regions on the DNA of target genes. DNA 
sequences of target genes are termed PPREs (per-
oxisome proliferator hormone response elements) 
which occur in the promoter of targeted genes 
with a consensus sequence like "AGGTCAXAG-
GTCA", (X is any nucleotide). Thus PPARs cause 
an increase or decrease in the transcription rates 
of target genes, depending on the gene’s function 
(6). The net functions of PPARs are modified by 
their ligand-binding domains which interact by a 
number of coactivator and corepressor proteins (7). 
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Free fatty acids and eicosanoids are among endog-
enous ligands for PPARs. The molecular structures 
of PPARs are comprised of the following domains: 
(A/B) N-terminal region, (C) DNA-binding do-
main (DBD), (D) flexible hinge region, (E) ligand 
binding domain (LBD) and (F) C-terminal region. 
DBD contains two zinc finger motifs which bind 
to specific sequences of DNA known as hormone 
response elements when the receptor is activated. 
The ligand binding domain contains an extensive 
secondary structure consisting of 13 alpha helices 
and a beta sheet (8, 9). Natural and synthetic lig-
ands bind to LBD, either activating or repressing 
the receptor (10, 11). 
As noted earlier, one of the members of the PPAR 
family is PPARγ. In mammals two PPARγ iso-
forms, PPARγ1 and PPARγ2, have been detected 
(12). Both isoforms are abundantly expressed in 
adipose tissue. PPARγ1 is detected at a lower level 
of expression in liver and heart tissues, while in 
skeletal muscle both types are expressed at low 
levels (13). PPARγ plays a key role in adipogen-
esis and adipocyte gene expression, and it is the 
receptor for the thiazolidinedione class of insulin-
sensitizing drugs (12). PPARγ exerts its function 
by binding to PPRE at the promoters of target 
genes. The mouse PPARγ gene has nine exons and 
extends more than 100 kilobases. Alternate tran-
scription start sites and alternate splicing generate 
PPARγ1 and PPARγ2 mRNAs, which differ at their 
5΄-ends. Thus PPARγ1 is encoded by eight exons, 
whereas PPARγ2 is encoded by seven exons. The 
5΄-untranslated sequence of PPARγ1 is comprised 
of exons A1 and A2, whereas that of PPARγ2 plus 
the additional PPARγ2-specific N-terminal amino 
acids are encoded by exon B, located between ex-
ons A2 and A1. The remaining six exons, termed 
1 to 6, are common to both PPARγ1 and γ2 (13). 
Due to various functions which are suggested for 
PPARγ, cloning of related cDNAs seems to be 
necessary since there is no evidence for the role of 
exogenous PPARγ in the process of neural cell dif-
ferentiation. Thus, the aim of this study is to clone 
PPARγ1 cDNA in a mammalian expression vector 
in a chimeric cDNA type, encompassing PPARγ 
with enhanced green fluorescent protein (EGFP) 
cDNA and determine the nuclear localization of the 
PPARγ protein when fused to an EGFP marker. 
Materials and Methods
RNA extraction
RNA was purified from the fatty tissue of a mouse 
(Souri strain) using RNX-PLUS kit (Cinnagen, 
Iran) as follows: 1ml RNX solution was added to 
5mg of wet tissue and the tissue was homogenized. 
At the next step, 200 μl choloroform was added 
to the homogenized tissue sample. After vigorous 
shaking and sedimentation at 13000 rpm for 15 
minutes at 4˚C, the upper phase was transferred 
to a fresh tube. RNA was precipitated by adding 
the same volume of isopropanol and centrifu-
gatin again at 13000 rpm for 15 minutes at 4˚C. 
The RNA solution was washed with 75% ethanol 
and dissolved in DEPC treated water. Total RNA 
concentration and quality was evaluated with OD 
absorption at 260 nm with a CE7250 spectropho-
tometer (Bioaquarius, UK) and agarose-gel elec-
trophoresis. 
cDNA synthesis and RT-PCR condition
In order to remove DNA contamination, 2 μg of 
extracted RNA was treated with DNaseI (Fermen-
tas, Lithuania) for 30 minutes at 37˚C. Then cDNA 
was synthesized using a cDNA synthesis kit (Fer-
mentas, Lithuania) according to the manufactur-
er’s protocol. Random hexamer primers (Fermen-
tas, Lithuania) were used in this study. RT-PCR for 
PPARγ1 cDNA amplification was done with 2 μl 
of first stranded cDNA in an Eppendorf Mastercy-
cler gradient thermal cycler (Eppendorf, Germany) 
using EX-taq DNA polymerase (Takara, Japan) as 
described below:
SOE-RT PCR (splicing by overlap extension-RT 
PCR) was used for amplifying the entire length of 
PPARγ1 cDNA. The SOE-RT PCR was performed 
in two-step PCR reactions as described below:
Step1: The first PCR step PCR was set to amplify 
two different fragments of PPARγ1 cDNA cover-
ing the whole length of related cDNA. The length 
of first fragment was 1033 bp which was amplified 
with primer pairs PPARγ1-F SacI and PPARγ1-
R-1021 (introducing SacI restriction site at the 5' 
end). A second 886 bp fragment was obtained in a 
PCR reaction with PPARγ1-R-KpnI and PPARγ1-
F-552 primer pair (introducing KpnI restriction 
site at the 3' end). Both fragments were purified 
by the QIAprep Spin Miniprep kit (Qiagen, Ger-
many) and used as the template for the next step.
Step2: The final stage for amplifying PPARγ1 
cDNA was a set of PCR with the last step prod-
ucts as template and using primer pairs PPARγ1-
F-SacI and PPARγ1-R-KpnI to produce the full 
length PPARγ1 cDNA (1428 bp). Moreover, in a 
different RT-PCR reaction with B-tubulin F and 
B-tubulin R primers, and with using a 2 μl cDNA 
template; we amplified a 318 bp fragment of B-
tubulin cDNA as a housekeeping gene to control 
RT-PCR cDNA synthesis steps.
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Plasmid constructions
In order to provide a suitable amount of PPARγ1 
cDNA, amplified PCR products were inserted into 
a pTZ57R/T vector (Fermentas, Lithuania, catalog 
# K1214) and transformed into E. coli competent 
cells. After blue/white colony selection, several pos-
itive colonies were chosen for plasmid extraction 
and sequence PPARγ1 cDNA analyses (Bioneer, 
Korea). Sequence checked recombinant plasmid 
was digested with SacI (Fermentas, Lithuania) and 
KpnI (Fermentas, Lithuania). The SacI-KpnI frag-
ment which contained PPARγ1 cDNA was ligated 
with a pEGFP-C1 vector at the related sites. Liga-
tion was carried out according to the Takara Liga-
tion kit, (TaKaRa, Japan). Ligation mixture was 
transformed into competent E. coli TOP10 (Invit-
rogen, USA). A colony-PCR experiment was done 
to isolate the recombinant pEGFP vector which 
contained a chimeric cDNA of PPARγ1 and EGFP 
termed pEGFP/ EGFP- PPARγ1. Whole steps are 
represented (Fig 1).
Cell culture and transient transfection condi-
tions
Bovine fibroblast cells were cultured in 10% 
DMEM-FCS (Gibco, USA) supplemented with 
100 U/ml penicillin under a humidified atmosphere 
at 5% CO2.
Bovine fibroblast cells (15000 cells/well) were 
plated in 24-well plates. Cells were grown on sterile 
glass coverslips in 24-well plates (TPP Company, 
Switzerland) and transfected with 800 ng of plas-
mid using Lipofectamine 2000 (Invitrogen, USA) 
according to the manufacturer’s instructions. The 
50 μl DNA-Lipofectamine complex was added to 
250 μl Opti-MEM I medium (Gibco, USA) pre-
washed cells and incubated for 6 hours, at 37ºC.
Fluorescence Microscopy
Two days post transfection, cells were washed in 
PBS and fixed for 30 minutes with 4% parafor-
maldehyde (Sigma, USA) in PBS. The cells were 
mounted with entellan (Merck, Germany). Fluo-
rescence images were obtained using a U-LH100-
HGAPO Olympus (BX51, Japan) fluorescence 
microscope.
Results
Target gene amplification 
Total RNA, from mouse fatty tissue which has 
been reported to show high expression of PPARγ, 
was extracted. The integrity of extracted RNA 
was evaluated after agarose gel electrophoresis. 
Three distinct ribosomal RNAs appeared in the 
gel as sharp bands (data not shown). To ensure the 
presence of cDNA synthesis stage, RT-PCR of a 
housekeeping gene, B-tubulin5, was done by us-
ing related specific primers (Table 1) that resulted 
in a sharp 318bp band which was absent in the 
control sample (Fig 1A, lane 1). 
RT-PCR was successful for amplifying two frag-
ments of PPARγ1 cDNA. Product sizes were 
as expected (Fig 2B, lanes 1 and 2). As previ-
ously described in materials and methods, the 
entire length of PPARγ1 cDNA (1428 bp) was 
produced at the second step of SOE-PCR (Fig 
2C) and cloned into a pTZ57R/T vector termed 
pTZ57R/T/ PPARγ1 cDNA. 
Table1: List of primers
Annealing 
temperatures 
used for PCR
Product 
length
PRIMER  SEQUENCEPRIMER NAME
63°C318 bp5' - TCACTGTGCCTGAACTTACC -3'FBeta tubulin
5'- GGAACATAGCCGTAAACTGC -3'RBeta tubulin
65°C1033 bp5'- ATTTGAGCTCAAGTTGACACAGAGATGCCATTCTG-3'
                    SacI
FPPARγ1-SacI
5'-GATGGAGTCCTCATCTCAGAGG-3'RPPARγ1-1021
60°C786 bp5'-GCCAACAGCTTCTCCTTCTCGGCC-3'FPPARγ1-552
5'- AATTGGTACCCTAATACAAGTCCTTGTAGATC -3'
                  KpnI
RPPARγ1-KpnI
70°C1450 bp5'- ATTTGAGCTCAAGTTGACACAGAGATGCCATTCTG-3'
                   SacI
FPPARγ1-SacI
5'- AATTGGTACCCTAATACAAGTCCTTGTAGATC  -3'
                    KpnI
RPPARγ1-KpnI
63°C676 bp5'- AACGAGAAGCGCGATCACATGC -3'FEGFP-C1
5'- GGCCGAGAAGGAGAAGCTGTTGGC  -3'RPPARγ1-575*
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Fig 1: RT-PCR products of b-tubulin and PPARγ1 fragments. A. Partial fragment of amplified b-tubulin cDNA (lane 1), lane 2 
is the control sample, lane 3 is blank; M is the marker (100 bp: Fermentas, Lithuania). B. Two amplified fragments of PPARγ1 
cDNA (lanes 1, 2); M is the marker (100 bp: Fermentas, Lithuania). C. The entire amplified PPARγ1 cDNA (lane 1); lane 2 is 
the negative control; M is the marker (100 bp: Fermentas, Lithuania). D. Schematic representation of the strategy for cloning 
PPARγ1 cDNA.
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Fig 2: Schematic  representation of PPARγ1 cDNA and protein sequences. A. ORF sequence 
of PPARγ1 cDNA. B. Produced amino acid residues of PPARγ1 cDNA. C. Partial sequence of 
PPARγ1 cDNA representing the 5'-part of PPARγ1 cDNA and SacI restriction site. D. Partial 
sequence of PPARγ1 cDNA representing the 3'-part of PPARγ1 cDNA and KpnI restriction site.
Positive colonies were identified by direct PCR 
approach. Sequence analysis of extracted plas-
mids on both strands indicated that the cDNA 
was 1428 bp in length with an ORF encoding a 
protein that consisted of 475 amino acids (Fig 
2) which confirmed that the cloned cDNA was a 
bonafide PPARγ1 cDNA without mutations. 
Transient transfection of pEGFP/EGFP-PPARγ1 
cDNA in bovine fibroblast cells
The whole fragment of PPARγ1 cDNA was pre-
pared by introduction into an appropriate eukary-
otic expression vector (pEGFP-C1) in order to 
be transfected into mammalian cells. Thus, both 
pEGFP-C1 and pTZ57R/T/ PPARγ1 cDNA were 
treated by two enzymatic cuts as described in the 
Fig 3: Enzymatic digestion of pTZ57/RT / PPARγ1 and pEGFP-C1 (A). Lane 1: undigested vectors, 
lane 2; after digestion with SacI, lane 3; SacI- KpnI cut, M is marker (1Kbp: fermentas, Lithuania). 
(B) Bacterial colony insert check results for finding pEGFP-C1/PPARγ1. 
Fig 4: Transient transfection of pEGFP-C1/PPARγ1 into bovine fibroblast cells. A-C. Transfect-
ed cells showing nuclear and cytosolic green fluorescence of EGFP-PPARγ1. Magnitude × 1000.
D. Transfected cells with EGFP-C1 plasmid. EGFP is dispersed into the cytosol. E. Negative con-
trol. No fluorescence observed in the cells.
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A
B
materials and methods section (Fig 3A, lanes 2 and 
3). The SacI-KpnI fragment, which comprised the 
whole length of PPARγ1 cDNA was placed at the 
corresponding sites in pEGFP-C1 with the same 
coding frame and downstream of EGFP cDNA. 
The resultant recombinant plasmid was termed 
pEGFP/EGFP-PPARγ1. The constructed vector 
was extracted from several positive bacterial colo-
nies (Fig 3B). Next, to assess intracellular localiza-
tion of the PPARγ1 protein, transient transfection 
of a plasmid that expressed the EGFP-PPARγ1 
chimeric protein was performed in bovine fibrob-
last cells. As green fluorescent protein (GFP) can 
be easily visualized under UV/blue light without 
any additional staining, cells were traced under UV 
fluorescent microscope. The bright green fluores-
cence was observed dominantly in the nucleus and 
to a lesser extent in the cytosol of transfected cells 
(Fig 4 A, B, C) emphasizing the main nuclear sort-
ing of PPARγ1. 
Discussion 
The SOE approach is a fast, simple, and extremely 
powerful way of recombining and modifying nu-
cleotide sequences (14). We have already used this 
approach to construct several truncated mutant 
forms of PEP cDNA (15). In this study, mouse 
PPARγ1 cDNA was cloned with the SOE PCR ap-
proach. This approach has currently been used for 
cloning of PPARγ1 cDNA from guinea pigs (16). 
PPARγ1 is highly expressed in mammalian adi-
pose tissue where it plays a critical regulatory role 
in adipocytes (17). Thus we used adipose tissue 
for RNA extraction leading to cDNA cloning of 
PPARγ1. Sequence data confirmed that the cloned 
cDNA fragment was a bonafide PPARγ1 cDNA as 
reported earlier (18). 
We have used the EGFP reporter gene to identify 
the intracellular localization of PPARγ1. GFP can 
be easily visualized under UV/blue light without 
any additional substrate or co-factor. Its assay is 
also non-destructive. Therefore, it has been widely 
used to monitor transgene expression and protein 
localization in a variety of cells and organisms 
(19). In our laboratory, EGFP have been used as 
a marker gene for indication of ectopic gene ex-
pression and intracellular destination of related 
proteins (20). Thus we have used the same tech-
nique for cloning PPARγ1. Using this recombinant 
vector which contains a chimeric form of EGFP 
PPARγ1, we will be able to chase the intracellular 
location of the PPARγ1 protein and examine its ec-
topic overexpression in the process of stem cell dif-
ferentiation. One major concern which remains to 
be clarified is that recombinant protein tagging can 
interfere with normal protein function or its intra-
cellular sorting, indicating the need for verifying 
its efficiency (21). To examine the functionality 
of EGFP- PPARγ1 and its intraclleular sorting, we 
have used a recombinant plasmid in this study for 
transfection into bovine fibroblast cells. In con-
firmation with previous data on mouse hepatoma 
and COS-1 cells (22, 23), our transfected pEGFP-
PPARγ1 localization data clearly demonstrated 
predominantly nuclear and cytosolic diffused dis-
tributions in bovine fibroblast cells. Thus, conclud-
ing that PPARγ1 is synthesized in the cytosol and 
imported to the nucleus in bovine fibroblast cells, 
verifying the proper function of the constructed 
recombinant plasmid. However in 3T3-L1 preadi-
pocytes and human peripheral blood monocytes, 
the high expression of PPARγ caused punctuate 
and perinuclear distribution of PPARγ (24, 25). 
Conclusion
Taken together, this study has established the nu-
clear localization of PPARγ1 in bovine fibroblast 
cells therefore demonstrating the correct targeting 
activity of an exogenous PPARγ1. Our constructed 
recombinant plasmid can be used for further stud-
ies to unravel additional metabolic functions of 
PPARγ since it can properly target into its destina-
tion which is the cell nucleus.
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